OLMA

Over the past six months, Olema Pharmaceuticals' stock (OLMA) has fallen by approximately 53.00%. Key events include a Q2 2026 earnings miss on August 10, 2026, reporting an EPS of -$0.61 against an estimated -$0.55, and a wider net loss of $63.2 million due to increased clinical development spending. The anticipated release of top-line data for the pivotal Phase 3 OPERA-01 trial was delayed from fall 2026 into the first quarter of fiscal year 2027. Jason O'Byrne was appointed Chief Financial Officer on August 13, 2026. The company also reported inducement grants under Nasdaq Listing Rule 5635(c)(4) on October 2, 2026, and September 2, 2026. As of October 1, 2026, the share price was $8.27, representing a 25.76% decline over the past year, with a 1-month change of -29.74% and a 3-month change of -36.32%. The 52-week high for OLMA was $36.26 and the low was $6.65.